Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

Study Overview
=================
Brief Summary
-----------------
This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.

Official Title
-----------------
Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis, Relapsing-Remitting

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants aged greater than or equal to (>/=) 18 years Participants who have a diagnosis of RRMS as documented in their medical records Participants who have been prescribed a DMT for at least 3 months Participants who have an expanded disability status scale (EDSS) score of 1-6 points Exclusion Criteria: - Participants with any personal or medical condition that in opinion of the investigator would interfere with or make impossible proper participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RRMS Population<br>Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants with Serious Adverse Events (Severe Life-Threatening or Less Severe) |  | Up to 3 months | 
| Percentage of Participants With DMT Administration Schedule Preferences |  | Up to 3 months | 
| Percentage of Participants With DMT Route of Administration Preferences |  | Up to 3 months | 
| DMT Efficacy Based on Annualized Relapse Rate |  | Up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants Education Level |  | Baseline | 
| Participants Employment Status |  | Baseline | 
| Participants RRMS Disease Duration |  | Baseline | 
| Number of Relapses of RRMS in Last 2 Years |  | Baseline | 
| Duration since Last Relapse of RRMS |  | Baseline | 
| Participants Current DMT for RRMS |  | Baseline | 
| Number of Previous DMTs Taken Prior to Switch to Current DMT |  | Baseline | 
| Expanded Disability Status Scale (EDSS) Score |  | Up to 3 months | 
| Health-Related Quality of Life Assessment Using Euro-Quality of Life 5 Dimension Questionnaire (EQ-5D) Scale Score |  | Up to 3 months | 
| Participant's Role in Decision Making measured by the Shared Decision Making Questionnaire 9-item version (SDM-Q-9) Score |  | Up to 3 months | 
| Cognitive performance as measured by the Medical Outcomes Study Cognitive Functioning Scale (MOS Cog-R) Score |  | Up to 3 months |